New phenotypes in hypersensitivity reactions to nonsteroidal anti-inflammatory drugs

被引:8
作者
Lee, Youngsoo [1 ]
Shin, Yoo Seob [1 ]
Park, Hae-Sim [1 ]
机构
[1] Ajou Univ, Dept Allergy & Clin Immunol, Sch Med, 164 Worldcup Ro, Suwon 16499, South Korea
关键词
adverse drug reaction; classification; hypersensitivity; nonsteroidal anti-inflammatory drug; phenotypes; EXACERBATED RESPIRATORY-DISEASE; ASPIRIN DESENSITIZATION; CHRONIC URTICARIA; ASTHMA; INTOLERANCE; NSAID; URTICARIA/ANGIOEDEMA; CLASSIFICATION; ACETAMINOPHEN; PATHOGENESIS;
D O I
10.1097/ACI.0000000000000541
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Purpose of review Nonsteroidal anti-inflammatory drug (NSAID) is one of the most frequently prescribed medications in the medical field, and hypersensitivity to NSAID is a common adverse drug reaction encountered. However, NSAID hypersensitivity presents a variety of symptoms caused by diverse pharmacological and immunological mechanisms. Recent findings Owing to the heterogeneity of the disease, a new concept for the classification of NSAID hypersensitivity has recently been proposed to diagnose and manage NSAID hypersensitivity for personalized treatment. Acute and delayed reactions were distinguished in this classification, and identification of symptoms and speculation of putative mechanisms help physicians make the right diagnosis. NSAID-exacerbated respiratory disease is a noticeable phenotype of NSAID hypersensitivity that involves upper airway comorbidities (chronic rhinosinusitis with nasal polyps) as well as asthmatic features. The cutaneous phenotypes of NSAID hypersensitivity occur, and cross-reactivity with other types of NSAID should be considered in establishing a proper diagnosis. Hypersensitivity to a single NSAID can present urticaria/angioedema and anaphylaxis, in which an IgE-mediated immune response is suggested to be a prime mechanism. Management of NSAID hypersensitivity reactions includes avoidance, pharmacological treatment following standard guidelines, and aspirin desensitization. Summary The classification, diagnosis, and management of NSAID hypersensitivity should be individually reached by identifying its phenotype.
引用
收藏
页码:302 / 307
页数:6
相关论文
共 52 条
[11]   Aspirin 300 mg/day is effective for treating aspirin-exacerbated respiratory disease [J].
Comert, S. ;
Celebioglu, E. ;
Yucel, T. ;
Erdogan, T. ;
Karakaya, G. ;
Onerci, M. ;
Kalyoncu, A. F. .
ALLERGY, 2013, 68 (11) :1443-1451
[12]   Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics [J].
Dahlén, B ;
Nizankowska, E ;
Szczeklik, A ;
Zetterström, O ;
Bochenek, G ;
Kumlin, M ;
Mastalerz, L ;
Pinis, G ;
Swanson, LJ ;
Boodhoo, TI ;
Wright, S ;
Dubé, LM ;
Dahlén, SE .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (04) :1187-1194
[13]   Improvement of asprinin-intolerant asthma by montelukast, a leukotriene antagonist -: A randomized, double-blink, placebo-controlled trial [J].
Dahlén, SE ;
Malmström, K ;
Nizankowska, E ;
Dahlén, B ;
Kuna, P ;
Kowalski, M ;
Lumry, WR ;
Picado, C ;
Stevenson, DD ;
Bousquet, J ;
Pauwels, R ;
Holgate, ST ;
Shahane, A ;
Zhang, J ;
Reiss, TF ;
Szczeklik, A .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 165 (01) :9-14
[14]   NSAID-induced urticaria/angioedema does not evolve into chronic urticaria: a 12-year follow-up study [J].
Dona, I. ;
Blanca-Lopez, N. ;
Torres, M. J. ;
Gomez, F. ;
Fernandez, J. ;
Zambonino, M. A. ;
Monteseirin, F. J. ;
Canto, G. ;
Blanca, M. ;
Cornejo-Garcia, J. A. .
ALLERGY, 2014, 69 (04) :438-444
[15]   Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs [J].
Dona, I. ;
Blanca-Lopez, N. ;
Jagemann, L. R. ;
Torres, M. J. ;
Rondon, C. ;
Campo, P. ;
Gomez, A. I. ;
Fernandez, J. ;
Laguna, J. J. ;
Rosado, A. ;
Blanca, M. ;
Canto, G. .
ALLERGY, 2011, 66 (11) :1428-1433
[16]   Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response [J].
Dona, I. ;
Blanca-Lopez, N. ;
Cornejo-Garcia, J. A. ;
Torres, M. J. ;
Laguna, J. J. ;
Fernandez, J. ;
Rosado, A. ;
Rondon, C. ;
Campo, P. ;
Agundez, J. A. ;
Blanca, M. ;
Canto, G. .
CLINICAL AND EXPERIMENTAL ALLERGY, 2011, 41 (01) :86-95
[17]   Aspirin-exacerbated respiratory disease: an update [J].
Duy Le Pham ;
Lee, Ji-Ho ;
Park, Hae-Sim .
CURRENT OPINION IN PULMONARY MEDICINE, 2017, 23 (01) :89-96
[18]   Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma [J].
Gevaert, Philippe ;
Calus, Lien ;
Van Zele, Thibaut ;
Blomme, Katrien ;
De Ruyck, Natalie ;
Bauters, Wouter ;
Hellings, Peter ;
Brusselle, Guy ;
De Bacquer, Dirk ;
van Cauwenberge, Paul ;
Bachert, Claus .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 131 (01) :110-U166
[19]   Sinonasal outcome under aspirin desensitization following functional endoscopic sinus surgery in patients with aspirin triad [J].
Havel, Miriam ;
Ertl, Lena ;
Braunschweig, Franziska ;
Markmann, Sabine ;
Leunig, Andreas ;
Gamarra, Fernando ;
Kramer, Matthias F. .
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2013, 270 (02) :571-578
[20]   Omalizumab reduces cysteinyl leukotriene and 9α,11β-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease [J].
Hayashi, Hiroaki ;
Mitsui, Chihiro ;
Nakatani, Eiji ;
Fukutomi, Yuma ;
Kajiwara, Keiichi ;
Watai, Kentaro ;
Sekiya, Kiyoshi ;
Tsuburai, Takahiro ;
Akiyama, Kazuo ;
Hasegawa, Yoshinori ;
Taniguchi, Masami .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (05) :1585-1587